Aligning hemodialysis treatment practices with the National Kidney Foundation's K/DOQI vascular access guidelines

Dialysis and Transplantation

Volumn 33, Issue 11, 2004, Pages 694-711

  Besarab, Anatole ^a,b   Brouwer, Deborah ^b,c  

^a HENRY FORD HOSPITAL   (United States)

^b NATIONAL KIDNEY FOUNDATION   (United States)

^c Renal Solutions   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALTEPLASE; ANTIBIOTIC AGENT; FIBRINOLYTIC AGENT; RETEPLASE; UROKINASE;

ALGORITHM; BLEEDING; BLOOD CLOT LYSIS; BLOOD FLOW; CANNULATION; CATHETER INFECTION; DRUG SAFETY; DRUG USE; FIBRINOLYTIC THERAPY; HEMODIALYSIS; HUMAN; KIDNEY ARTERIOVENOUS FISTULA; KIDNEY FAILURE; MEDICAL SOCIETY; OCCLUSION; PATIENT MONITORING; PRACTICE GUIDELINE; PREVALENCE; PRIORITY JOURNAL; REVIEW; SEPTICEMIA; VASCULAR PATENCY;

EID: 8144221270     PISSN: 00902934     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (41)

1. United States Renal Data System. 2003 Annual Data Report/Atlas (Précis). Available at: http://www.usrds.org/2003/pdf/0B_precis_03.pdf. Accessed May 3, 2004.
2. United States Renal Data System. USRDS 2000 Annual Data Report/Atlas. Available at: http://www.usrds.org/2kpdf/11_economics.pdf. Accessed December 31, 2003.
3. Eknoyan G, Levin NW. Impact of the new K/DOQI guidelines. Blood Purif 2002; 20:103-108.
4. National Kidney Foundation. NKF-K/DOQI Clinical Practice Guidelines for Vascular Access: update 2000. Am J Kidney Dis 2001; 37:S137-S181.
5. Centers for Medicare & Medicaid Services. 2002 Annual Report. ESRD Clinical Performance Measures Project. Baltimore, MD: Department of Health and Human Services, Centers for Medicare & Medicaid Services, Center for Beneficiary Choices; December 2002. Available at: http://www.cms.hhs.gov/esrd/1. asp#5. Accessed May 25, 2004.
6. Hakim RM, Breyer J, Ismail N, Schulman G. Effects of dose of dialysis on morbidity and mortality. Am J Kidney Dis 1994; 23:661-619.
7. Work J. Hemodialysis catheters and ports. Semin Nephrol 2002; 22:211-220.
8. Allon M, Robbin ML. Increasing arteriovenous fistulas in hemodialysis patients: problems and solutions. Kidney Int 2002; 62:1109-1124.
9. Windus DW, Audrain J, Vanderson R, Jendrisak MD, Picus D, Delmez JA. Optimization of high-efficiency hemodialysis by detection and correction of fistula dysfunction. Kidney Int 1990; 38:337-341.
10. Begin V, Ethier J, Dumont M, Leblanc M. Prospective evaluation of the intra-access flow of recently created native arteriovenous fistulae. Am J Kidney Dis 2002; 40:1277-1282.
11. Besarab A, Sullivan KL, Ross RP, Moritz MJ. Utility of intra-access pressure monitoring in detecting and correcting venous outlet stenoses prior to thrombosis. Kidney Int 1995; 47:1364-1373.
12. Magnasco A, Alloatti S, Martinoli C, Solari P. Glucose pump test: a new method for blood flow measurements. Nephrol Dial Transplant 2002; 17:2244-2248.
13. Ronco C, Brendolan A, Crepaldi C, D'Intini V, Sergeyeva O, Levin NW. Noninvasive transcutaneous access flow measurement before and after hemodialysis: impact of hematocrit and blood pressure. Blood Purif 2002; 20:376-379.
14. Suhocki PV, Conlon Jr PJ, Knelson MH, Harland R, Schwab SJ. Silastic cuffed catheters for hemodialysis vascular access: thrombolytic and mechanical correction of malfunction. Am J Kidney Dis 1990; 28:379-386.
15. Konner K. Increasing the proportion of diabetics with AV fistulas. Semin Dial 2001; 14:1-4.
16. Sands J, Perry M. Where are all the AV fistulas? Semin Dial 2002; 15:146-148.
17. National Kidney Foundation. NKF-K/DOQI Clinical Practice Guidelines for Chronic Kidney Disease: Evaluation, Classification, and Stratification. Am J Kidney Dis 2002; 39:S45, S70-S71.
18. National Vascular Access Improvement Initiative. Boston, MA: Institute for Healthcare Improvement. Available at: http://www.esrdnet5.org/ NAII%20Chapter.pdf. Accessed May 12, 2004.
19. United States Renal Data System. USRDS 1997 Annual Data Report. Available at: http://www.usrds.org/adr_1997.htm. Accessed May 7, 2004.
20. Taylor G, Gravel D, Johnston L, Embil J, Holton D, Paton S. Prospective surveillance for primary bloodstream infections occurring in Canadian hemodialysis units. Infect Control Hosp Epidemiol 2002; 23:716-720.
21. Raad II, Luna M, Khalil SA, Costerton JW, Lam C, Bodey GP. The relationship between the thrombotic and infectious complications of central venous catheters. JAMA 1994; 271:1014-1016.
22. Carratala J. Role of antibiotic prophylaxis for the prevention of intravascular catheter-related infection. Clin Microbiol Infect 2001; 7:83-90.
23. Whitman ED. Complications associated with the use of central venous access devices. Curr Probl Surg 1996; 33:309-378.
24. Beathard GA. Management of bacteremia associated with tunneled-cuffed hemodialysis catheters. J Am Soc Nephrol 1999; 10:1045-1049.
25. Quarello F, Forneris G. Prevention of hemodialysis catheter-related bloodstream infection using an antimicrobial lock. Blood Purif 2002; 20:87-92.
26. Ayus JC, Sheikh-Hamad D. Silent infection in clotted hemodialysis access grafts. J Am Soc Nephrol 1998; 9:1314-1317.
27. Clarke DE, Raffin TA. Infectious complications of indwelling long-term central venous catheters. Chest 1990; 97:966-972.
28. Krivitski NM, Gantela S. Access flow measurement as a predictor of hemodialysis graft thrombosis: making clinical decisions. Semin Dial 2001; 14:181-185.
29. Lilly RZ, Carlton D, Barker J, Saddekni S, Hamrick K, Oser R, Westfall AO, Allon M. Predictors of arteriovenous graft patency after radiologic intervention in hemodialysis patients. Am J Kidney Dis 2001; 37:945-953.
30. Fan PY, Schwab SJ. Vascular access: concepts for the 1990s. J Am Soc Nephrol 1992; 3:1-11.
31. Tokars JI, Frank M, Alter MJ, Arduino MJ. National surveillance of dialysis-associated diseases in the United States, 2000. Centers for Disease Control and Prevention, Department of Health and Human Services, Atlanta, GA. Available at: http://www.cdc.gov/ncidod/hip/Dialysis/dialysis00_notags.pdf. Accessed January 9, 2004.
32. Haire WD, Atkinson JB, Stephens LC, Kotulak GD. Urokinase versus recombinant tissue plasminogen activator in thrombosed central venous catheters: a double-blinded, randomized trial. Thromb Haemost 1994; 72:543-547.
33. Ponec D, Irwin D, Haire WD, Hill PA, Li X, McCluskey ER. Recombinant tissue plasminogen activator (alteplase) for restoration of flow in occluded central venous access devices: a double-blind placebo-controlled trial: the Cardiovascular Thrombolytic to Open Occluded Lines (COOL) efficacy trial. J Vasc Interv Radiol 2001; 12:951-955.
34. Deitcher SR, Fesen MR, Kiproff PM, Hill PA, Li X, McCluskey ER, Semba CP. Safety and efficacy of alteplase for restoring function in occluded central venous catheters: results of the Cardiovascular Thrombolytic to Open Occluded Lines Trial. J Clin Oncol 2002; 20:317-324.
35. Clase CM, Crowther MA, Ingram AJ, Cina CS. Thrombolysis for restoration of patency to haemodialysis central venous catheters: a systematic review. J Thromb Thrombolysis 2001; 11:127-136.
36. Eyrich H, Walton T, Macon EJ, Howe A. Alteplase versus urokinase in restoring blood flow in hemodialysis-catheter thrombosis. Am J Health Syst Pharm 2002; 59:1437-1440.
37. Atkinson JB, Bagnall HA, Gomperts E. Investigational use of tissue plasminogen activator (t-PA) for occluded central venous catheters. J Parenter Enteral Nutr 1990; 14:310-311.
38. Castner D. The efficacy of reteplase in the treatment of thrombosed hemodialysis venous catheters. Nephrol Nurs J 2001; 28:403-410.
39. Cynamon J, Lakritz PS, Wahl SI, Bakal CW, Sprayregen S. Hemodialysis graft declotting: description of the "lyse and wait" technique. J Vasc Interv Radiol 1997; 8:825-829.
40. Vogel PM, Bansal V, Marshall MW. Thrombosed hemodialysis grafts: Lyse and wait with tissue plasminogen activator or urokinase compared to mechanical thrombolysis with the Arrow-Trerotola Percutaneous Thrombolytic Device. J Vasc Interv Radiol 2001; 12:1157-1165.
41. United States Renal Data System. 2002 Annual Data Report/Atlas. Available at: http://www.usrds.org/atlas_2002.htm. Accessed December 31, 2003.